RCT evidence driven mediocristan vs individual PaJR precision driven extremistan!

Summary

The transcript captures a conceptual discussion applying Nassim Taleb’s ideas of "Mediocristan" and "Extremistan" to the evolution of medical practice. The speakers draw a parallel between traditional, Randomized Controlled Trial (RCT)-driven medicine, which relies on predictable averages and bell curves (Mediocristan), and the emerging field of precision medicine driven by Patient Journey Records (PaJR). They conclude that standard medical practice will gradually be supplemented—and potentially overtaken—by this highly individualized, "Extremistan" approach, which accommodates extreme variables and unique patient data rather than relying solely on the statistical average.

Keywords

• Concepts: Mediocristan, Extremistan, The Black Swan (Nassim Taleb), Paradigm Shift.

• Medical Terms: Randomized Controlled Trials (RCTs), Patient Journey Records (PaJR), Precision Medicine, Evidence-Based Medicine.

• Statistical Terms: Bell Curve, Average, Constrained vs. Wild Randomness.

---

Thematic Analysis: The Shift from Mediocristan to Extremistan Medicine

1. The "Mediocristan" Paradigm of Mainstream Medicine (RCTs)

Currently, Evidence-Based Medicine relies heavily on the "gold standard" of Randomized Controlled Trials (RCTs). RCTs are inherently built for Mediocristan. They are designed to constrain randomness, eliminate outliers, and find the statistical average to determine if a treatment works for the "typical" patient. Like the height of people in a room, RCT data usually falls on a bell curve. While this has been incredibly effective for public health and broad medical guidelines, it fundamentally struggles with the individual. Every individual patient is a biological outlier and "average" treatment can often fail them completely.

2. The "Extremistan" Frontier of Precision Medicine (PaJR)

Precision medicine, powered by robust Patient Journey Records (PaJR), operates in Extremistan. PaJRs capture an individual's unique environment, lifestyle, and longitudinal health data.https://pmc.ncbi.nlm.nih.gov/articles/PMC12688023/, 

In this realm, randomness is "wild." A unique combination of comorbidities (the biological equivalent of treating every patient as Jeff Bezos or Julia Roberts in terms of how extremely special they are taking care to share their details with collective cognition and science in a manner to keep them unidentifiable and yet promote transparency and accountability) can exponentially alter a patient's health trajectory and their response to treatment. PaJR-driven medicine acknowledges that human biology is deeply complex and that outlier events (medical "Black Swans") require hyper-individualized, exploratory treatment plans rather than average-based protocols.

3. The Friction of Acceptance (Why Extremistan is Hard to Swallow)

As you noted, transitioning to this new model will be difficult for both people and institutions to accept. This friction stems from several factors:

• Institutional Inertia: The entire medical, insurance, and regulatory apparatus is built to fund, approve, and reimburse treatments based on RCTs (Mediocristan). Approving an "N-of-1" exploratory treatment based on a specific patient's PaJR disrupts this deeply ingrained system.

• Human Psychology: As Taleb points out, humans are naturally drawn to the comfort of predictability and the illusion of certainty that bell curves provide. "Extremistan" medicine requires doctors and patients to embrace a degree of exploratory uncertainty and wild randomness, which feels riskier than following a standard flowchart.

4. The Inevitable Paradigm Shift

The transcript hits the nail on the head: "RCT evidence driven mediocristan mainstream medicine will be gradually supplemented more and more by individual PaJR precision driven exploratory extremistan medicine!" We are moving from treating the disease (based on how the average human reacts to it) to treating the patient (based on their specific data). As data tracking (wearables, genome sequencing, AI analysis of PaJRs) becomes cheaper and more precise, the inability of RCTs to treat outliers will become glaringly obvious. Precision medicine will start by dominating fields with high variability, like oncology and rare diseases, before eventually replacing mediocristan approaches as the baseline standard of care.

---

Conversational transcripts:

[20/03, 03:53]hu1: Wonder what you think of this applying to RCTs

[20/03, 09:22]hu2: Spoiler alert if you haven't finished this book already!

"To explain how and why Black Swans occur, Taleb coins two categories to describe the measurable facets of existence: Extremistan and Mediocristan. 

In Mediocristan, randomness is highly constrained, and deviations from the average are minor. Physical characteristics such as height and weight are from Mediocristan: They have upper and lower bounds, their distribution is a bell curve, and even the tallest or lightest human being isn’t much taller or lighter than the average. In Mediocristan, prediction is possible.

In Extremistan, however, randomness is wild, and deviations from the average can be, well, extreme. Most social, man-made aspects of human society—the economy, the stock market, politics—hail from Extremistan: They have no known upper or lower bounds, their behavior can’t be graphed on a bell curve, and individual events or phenomena—i.e., Black Swans—can have exponential impacts on averages.

Imagine you put ten people in a room. Even if one of those people is Shaquille O’Neal, the average height in the room is likely to be pretty close to the human average (Mediocristan). If one of those people is Jeff Bezos, however, suddenly the wealth average changes drastically (Extremistan)"

[20/03, 13:20]hu1: That was in the next page! 😅

[21/03, 15:43]hu2: 

Essential bottom-line:

RCT evidence driven mediocristan mainstream medicine will be gradually supplemented more and more by individual PaJR precision driven exploratory extremistan medicine!

[21/03, 15:46]hu1: Yes and now with this context, I was just thinking a diagnosis of hepatitis for our current PaJR patient was back to system 1 and non-PaJR driven rather than sequential event driven?

Or were you thinking those fruits had some dodgy pesticides?

[21/03, 16:21]hu2: Agree the hepatitis was a typical mediocristan approach that may have worked sometimes in the past with offline workarounds where one can quickly look at the whole patient's events something that online asynchronous windows don't afford.

Which makes me think perhaps a majority of mainstream medicine that was practiced offline actually didn't need system 2 precision largely because they had the patient at hand to clarify but again as facilities expanded the very structure of healthcare underwent a sea change to make this access to the whole patient itself a luxury!

Conversational citations:

[21/03, 17:21]hu1: @⁨all 

What factors do you think are causing this abject lack of data sharing? Do you think this attitude carries over into a lackadaisical approach to health care and its outcomes as well?

[21/03, 19:05]hu2: Agree! It does and the other reason is as shared earlier, the fact that mainstream medicine is still synchronous dyadic that keeps all the data circulating between the patients and their local providers. 

Often as the data is not part of a collective stream of evidence, local knowers of the data gain an extremistan "expertise" that a global data starved evidence base cannot and slowly withers into mediocristan.

https://medicinedepartment.blogspot.com/2026/03/rct-evidence-driven-mediocristan-vs.html?m=1